North America Ophthalmology Market - Industry Trends and Forecast to 2032

North America Ophthalmology Market Analysis

The North America ophthalmology market has evolved significantly over the centuries, beginning with ancient treatments for eye conditions in Egypt and Greece. The field began to take shape in the 17th and 18th centuries, with the development of more advanced surgical techniques and tools. In the 19th century, innovations like the ophthalmoscope transformed diagnostic capabilities. The 20th century saw breakthroughs such as cataract surgery and the invention of intraocular lenses, along with the advent of LASIK surgery in the 1990s. The 21st century brought continued growth driven by an aging population, technological advancements, and the development of specialized diagnostic and surgical devices, including optical coherence tomography (OCT) and retinal imaging systems. Recent trends focus on the increasing use of artificial intelligence, telemedicine, and biologic therapies, such as gene therapy and stem cell treatments, further shaping the market's growth. Today, the ophthalmology market continues to expand due to rising eye disease prevalence, new technologies, and evolving treatment options.

North America Ophthalmology Market Size

The North America ophthalmology market is expected to reach USD 52.37 billion by 2032 from USD 31.77 billion in 2024, growing at a CAGR of 6.5% in the forecast period of 2025 to 2032.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

 North America Ophthalmology Market Trends

“The Growing Adoption of Telemedicine and AI-Powered Diagnostic tools”

The North America ophthalmology market is the growing adoption of telemedicine and AI-powered diagnostic tools. These innovations are transforming the way eye care is delivered by enabling remote consultations and screenings, which increases accessibility, especially in underserved and rural areas. AI technologies, including machine learning algorithms, are being used to analyze retinal images, detect early signs of conditions like diabetic retinopathy, glaucoma, and macular degeneration, and provide faster, more accurate diagnoses. Telemedicine platforms allow patients to connect with ophthalmologists for follow-up consultations, reducing the need for in-person visits and making eye care more convenient and efficient. This trend is not only improving patient access to timely treatments but also enhancing the overall efficiency of healthcare systems, making it a key driver of market growth in the ophthalmology sector. As a result, the integration of these technologies is expected to continue expanding, particularly in emerging markets, where healthcare infrastructure is still developing.

Report Scope and North America Ophthalmology Market Segmentation      

North America Ophthalmology Market Definition

Ophthalmology is a branch of medicine and surgery that focuses on the diagnosis, treatment, and prevention of eye disorders and diseases. It includes medical and surgical care for conditions affecting the eyes and visual systems, such as cataracts, glaucoma, macular degeneration, and diabetic retinopathy.

North America Ophthalmology Market Definition Dynamics

Drivers  

• Increasing Prevalence of Eye Diseases

The increasing prevalence of eye conditions, such as cataracts, macular degeneration, and diabetic retinopathy, is a significant driver of the North America ophthalmology market. As the North America population ages, the incidence of these conditions is rise. Cataracts, which lead to blurred vision and blindness, demand an expanding market for surgeries and corrective treatments. Similarly, macular degeneration and diabetic retinopathy are contributing to the need for advanced diagnostic tools and specialized therapies. The growing number of affected individuals ensures sustained demand for eye care services, including surgeries, medications, and innovative diagnostic technologies. This surge in eye diseases directly drives market expansion, as healthcare providers and manufacturers strive to meet the growing need for effective treatments and solutions.

For instance,

• In July 2022, according to the article published by NCBI, The prevalence of blindness rises with age, increasing from 0.45% in those aged 50-59 to 11.62% in individuals 80 and older. Females (2.31%) and rural residents (2.14%) experience higher rates. Visual impairment also affects 26.68% of participants, showing similar trends. This growing burden of eye diseases, particularly among the elderly, drives demand for ophthalmic treatments and technologies, boosting the ophthalmology market
• In August 2023, according to the article published by WHO, North America, over 2.2 billion people suffer from vision impairment, with nearly 1 billion cases being preventable or untreated. This growing prevalence of vision issues highlights the increasing demand for eye care services, treatments, and corrective solutions. As more people seek medical attention for preventable or unresolved conditions, the rising burden of eye diseases acts as a significant driver for the ophthalmology market

The rising prevalence of age-related eye conditions like cataracts, macular degeneration, and diabetic retinopathy is fueling the North America ophthalmology market. As the population ages, these diseases become more common, increasing the demand for treatments, surgeries, and diagnostic tools. The need for advanced technologies and therapies grows as more people require care. This surge in eye conditions drives market growth, as healthcare providers and manufacturers aim to meet the rising demand for effective solutions.

• Focus on Preventative Eye Care  

There is a growing emphasis on preventative eye care and early detection of vision-related issues, which is playing a significant role in driving the North America ophthalmology market. As awareness about the importance of eye health increases, more people are seeking routine eye checkups to detect conditions like glaucoma, diabetic retinopathy, and cataracts in their early stages. Early diagnosis allows for timely interventions, reducing the risk of vision loss and improving overall eye health. This proactive approach is not only improving patient outcomes but also fueling demand for ophthalmic services, diagnostic tools, and corrective treatments. The growing focus on preventative care is leading to a surge in investments in eye care technologies, ophthalmic devices, and services, thereby contributing to the market's expansion. This trend strongly acts as a driver for growth in the ophthalmology sector.

For instance,

• In October 2022, according to the article published by National Eye Institute, National Eye Health Education Program(NEHEP) collaborates with health professionals to promote awareness on early detection, treatment of eye diseases, and the benefits of vision rehabilitation. It also targets populations at high risk of eye disease and vision loss. This focus on preventative care encourages people to seek timely eye checkups and treatments, driving demand for ophthalmic services, diagnostic tools, and products, thereby fueling the ophthalmology market
• In October 2024, according to the article published by Directorate General of Health Services, The National Programme for Control of Blindness and Visual Impairment (NPCB&VI) aims to reduce blindness prevalence by identifying and treating curable blindness at all healthcare levels. By focusing on early detection and addressing avoidable blindness, the program highlights the importance of preventative care. This initiative drives demand for eye care services, diagnostic tools, and treatments, contributing significantly to the growth of the North America ophthalmology market

The increasing focus on preventative eye care and early detection is significantly driving the North America ophthalmology market. As awareness of eye health rises, more individuals are opting for routine eye exams to identify conditions like glaucoma and cataracts early. Early detection allows for effective treatments that prevent further vision loss. This proactive approach is driving demand for diagnostic tools, ophthalmic services, and corrective treatments. The growing importance of preventative care is prompting investment in advanced eye care technologies, thus contributing to the overall growth of the ophthalmology market and ensuring its continued expansion.

Opportunities

• Rise in the Aging Population

The rise in the aging population presents a significant opportunity for the North America ophthalmology market, as older individuals are more susceptible to various eye disorders and diseases. Conditions such as cataracts, age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma are prevalent among the elderly, creating a substantial demand for ophthalmic care and treatments. As a result, healthcare systems and ophthalmic providers are poised to expand their services, enhance diagnostic and therapeutic options, and cater to the unique needs of this demographic. This growing patient base necessitates an array of solutions, from surgical interventions and advanced drug therapies to vision correction products, ensuring a steady and increasing demand for ophthalmic procedures and products.

For instance,

• In March 2023, according to an article published in the National Library of Medicine, Cataract is a leading cause of visual impairment in old age. Lens opacification is notoriously associated with several geriatric conditions, including frailty, fall risk, depression and cognitive impairment. Moreover, according to the same source, in 2020, the leading worldwide causes of blindness in patients aged 50 years and older were cataract, followed by glaucoma, under-corrected refractive error, age-related macular degeneration, and diabetic retinopathy
• In August 2022, according to an article published in the American Academy of Ophthalmology, AMD is a common eye disease, usually found in adults over the age of 50. Moreover, it is stated that Half of Americans over the age of 75 develop cataracts

Moreover, addressing the eye health needs of the aging population can stimulate further investments in research and development within the ophthalmology sector. Pharmaceutical companies and medical device manufacturers are focus on creating innovative solutions tailored specifically for age-related conditions, potentially leading to breakthroughs in treatment protocols and patient care. The integration of new technologies, such as tele ophthalmology and advanced imaging techniques, facilitate better management of eye health in older adults, making it easier to monitor and treat conditions remotely. Overall, the aging population amplifies the need for existing ophthalmic services and presents a fertile ground for innovation and growth within the North America ophthalmology market.

• Rise in Online Retail and E-Health Platforms

The rise of online retail and e-health platforms offers a significant opportunity for the North America ophthalmology market by providing consumers with easier access to a wide array of eye care products and services. With the increasing adoption of e-commerce, patients can conveniently purchase items such as prescription glasses, contact lenses, and over-the-counter eye care products from the comfort of their homes. This trend is especially appealing to younger, tech-savvy consumers and those in remote areas with limited access to traditional optical stores. The ability to compare prices, read reviews, and access a wider range of products online enhances customer satisfaction and encourages usage, thereby driving growth in the ophthalmic product segment.

For instance,

• In September 2023, according to a news article from The Times of India, the 'pink eye' outbreak led to a surge in sales of ophthalmology medicine. Sales jumped nearly 30% year-on-year for the second month in a row in August - outgrowing the overall market by almost five times. The rise reflects the massive incidence of conjunctivitis and eye-complications in the last few months across the country
• In April 2020, according to an article, ‘Patient views about online purchasing of eyewear’, online purchasing of contact lenses is on the rise: 10%–20% of contact lens wearers in Australia, U.S. and the UK have considered or researched the possibility of Internet purchasing

In addition to retail opportunities, e-health platforms facilitate telehealth services that allow patients to consult with eye care professionals remotely. Virtual consultations for routine eye examinations, follow-ups, and triaging for more serious conditions can significantly improve access to care, particularly for older adults or individuals with mobility challenges. These platforms enhance patient engagement and adherence to eye health recommendations and allow ophthalmologists to reach a broader patient base without the constraints of geographic boundaries. Furthermore, the integration of digital health tools, such as mobile apps for monitoring eye health or managing chronic conditions, can create a seamless patient experience and foster proactive eye care, further propelling growth in the ophthalmology market.

Restraints/Challenges

• Side Effects and Complications Related to Eye Surgeries

Despite the significant advancements in ophthalmology treatments, certain ophthalmic procedures, particularly surgical interventions, carry risks of side effects and complications such as infection, scarring, or vision impairment. These potential risks can deter patients from undergoing specific therapies, especially those that involve invasive procedures. The fear of adverse outcomes, such as reduced vision or prolonged recovery times, can lead to hesitancy in seeking treatment, limiting the overall adoption of certain therapies. Additionally, complications arising from surgeries might require additional treatments, further raising healthcare costs and impacting patient trust in advanced treatments. This reluctance to undergo treatments due to the potential for negative side effects restricts the overall growth of the ophthalmology market by slowing down the adoption of new technologies and therapies. 

For instance,

• In October 2024, according to the article published by Harvard Health, Modern eye surgeries, while effective in treating conditions like cataracts and glaucoma, often lead to complications such as dry eye disease, characterized by a burning, gritty, or itchy sensation. This side effect can be uncomfortable and discouraging for patients, leading some to hesitate or avoid eye surgeries. As a result, complications from treatments act as a restraint on the growth of the ophthalmology market
• In July 2021, according to the article published by Medical News Today, Up to 95% of individuals who undergo laser eye surgery may experience dry eyes, while 20% report visual disturbances like glare or halos. Additionally, 1 in 50 people may suffer from blurry vision or “sands of Sahara” syndrome. These side effects can discourage patients from opting for surgery, limiting the adoption of laser procedures and acting as a restraint on the ophthalmology market’s growth

Despite advancements in ophthalmology, some surgical treatments carry risks such as infection, scarring, or vision impairment. These complications can discourage patients from opting for certain therapies, particularly invasive procedures. The fear of adverse outcomes and additional treatment costs can hinder patient willingness to seek care, slowing the adoption of new treatments. This reluctance limits the growth of the North America ophthalmology market.

• Limited Access to specialized Ophthalmic Care in Rural Areas

Despite advancements in healthcare infrastructure, access to specialized ophthalmic care remains limited in rural and remote areas, significantly hindering the growth potential of the ophthalmology market in these regions. Many rural populations still face challenges such as a lack of trained eye care professionals, inadequate facilities, and limited access to advanced diagnostic and treatment technologies. As a result, individuals in these areas often struggle to receive timely diagnosis and treatment for eye conditions, leading to a higher incidence of preventable blindness and vision impairment. The limited availability of specialized care restricts market expansion by reducing the adoption of advanced eye care services and products. This barrier to access continues to act as a major restraint on the North America ophthalmology market’s overall growth.

For instance,

• In February 2023, according to the article published by NCBI, India's large rural population faces significant unmet eye care needs, with most facilities and professionals concentrated in urban and semi-urban areas. The disparity in access to eye care between rural and urban regions remains a challenge, limiting treatment availability. This unequal distribution of healthcare resources restricts the growth of the North America ophthalmology market by preventing widespread access to essential services in rural areas
• In March 2024, according to the article published by Research Gate, The lack of connectivity and trained staff in remote areas hampers access to continuous eye care, even after successful eye camps. Patients in these areas struggle to receive follow-up care or advanced treatments due to the absence of proper infrastructure. This gap in healthcare delivery limits the reach and effectiveness of eye care programs, acting as a restraint on the North America ophthalmology market's growth

Access to specialized eye care is still limited in rural areas, despite healthcare improvements. The shortage of eye care professionals, advanced technology, and facilities prevents timely treatment and diagnosis, leading to higher rates of avoidable blindness. This limited access hampers the growth of the North America ophthalmology market by restricting adoption of advanced treatments and services in these regions.

North America Ophthalmology Market Scope

The market is segmented on the basis of products, diseases, comprehensive eye examination, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

By Products

• Device
  • Surgical Device
    • Cataract Surgical Devices
    • Ophthalmic Viscoelastic Devices
      • Phacoemulsification Devices
      • Cataract Surgical Lasers
      • IOL Injectors
    • Vitreoretinal Surgical Devices
      • Vitrectomy Machines
      • Vitreoretinal Packs
      • Photocoagulation Lasers
      • Vitrectomy Probes
      • Illumination Devices
    • Refractive Surgical Devices
      • Femtosecond Lasers
      • Excimer Lasers
      • Other Refractive Surgical Lasers
    • Glaucoma Surgical Devices
      • Glaucoma Drainage Devices
      • Microinvasive Glaucoma Surgery Devices
      • Glaucoma Laser Systems
  • Diagnostic Device
    • Optical Coherence Tomography (OCT) Scanners
    • Autorefractors & Keratometers
    • Tonometers
    • Phoropters
    • Retinoscopes
    • Ophthalmoscopes
    • Slit lamps
    • Perimeters/Visual Field Analyzers
    • Corneal Topography Systems
    • Fundus Cameras
    • Ophthalmic Ultrasound Imaging Systems
      • A- Scan Imaging System
      • B-Scan Imaging System
      • Pachymeters
      • Ultrasound Biomicroscopes
    • Lensmeters
    • Wavefront Aberrometers
    • Optical biometry Systems
    • Specular Microscopes
    • Chart Projectors
  • Ophthalmic Surgical Accessories
    • Surgical Instruments & Kits
    • Ophthalmic Forceps
    • Ophthalmic Spatula
    • Ophthalmic Tips and Handles
    • Ophthalmic Cannulas
    • Ophthalmic Scissors
    • Others Surgical Accessories
  • Ophthalmic Microscopes
• Drugs, By Products
  • Anti-VEGF Drugs
    • Ranibizumab
    • Bevacizumab
  • Retinal Disorder Drugs
  • Anti-Glaucoma Drugs
    • Prostaglandin Analogs
      • Latanoprost
      • Bimatoprost
      • Travoprost
      • Tafluprost
      • Latanoprostene
    • BETA Adrenergic Antagonists
      • Timolal Maleate
      • Betaxolol
    • Alpha Adrenergic Agonists
      • Epinephrine
      • Depiveprine
    • Miotics
      • Pilocarpine
      • Eserine
  • Dry Eye Drugs
  • Anti-Inflammatory Drugs
    • Steroidal anti-Inflammatory Drugs
    • Non-steroidal Anti-Inflammatory Drugs
  • Allergic Conjuctivitis Drugs
  • Others
• Drugs, By Drug Type
  • Branded
  • Generic
• Drugs, By Presciption Mode
  • Prescription
  • Over the Counter
• Drugs, By Route of Administration
  • Topical
    • Eye Drops
    • Eye Solution
    • Cream & Ointments
    • Gel
    • Others
  • Local Ocular
    • Intravitreal
    • Subconjunctival
    • Retrobulbar
    • Intracameral
  • Injectables
    • Intramuscular
    • Intravenous
    • Others
  • Oral
    • Tablet
    • Capsules
    • Others
  • Others
• Others
  • Vision Care Products
    • Spectacles
    • Contact Lenses
      • Soft Contact Lenses
      • Hybrid Contact Lenses
      • Rigid Gas Permeable Lenses
  • Others

By Diseases

• Cataract
• Refractive Disorders
• Glaucoma
• Age-related Macular Degeneration
• Inflammatory Diseases
• Others

By Comprehensive Eye Examination

• Refraction
  • Automated Refractometers
  • Set of Trial Lenses
  • Cycloplegic Drugs
  • Trial Frame
  • Self-Illuminated/ Mirror Retinoscope
  • Jackson Cross Cylinder
• Visual Acuity Test
  • Snellen's Chart
  • Near Vision Charts
• Intraocular Pressure
  • Tonometers (Goldmann, Tono-Pen, Perkins, Shiotz)
  • Others
• Anterior Segment and Pupillary Examination
  • Slit Lamp Biomicroscope
  • Torch Light
• Visual Fields Test
  • Central 30-2 Full Threshold Humphrey Visual Field Analyzer
  • Frequency Doubling Perimeter
  • Goldmann Kinetic Perimeter
• Color Vision Test
• Others

By End User

• Clinics
• Hospitals
• Home Healthcare
• Others

By Distribution Channel

• Retail sales
  • Retail Shops
  • Hospital Pharmacy
  • Online Pharmacy
• Direct Tender
• Others

North America Ophthalmology Market Regional Analysis

The market is segmented on the basis of products, diseases, comprehensive eye examination, end user, and distribution channel.

The countries covered in this market are U.S, Canada, and Mexico.

U.S. is expected to dominate the market due to advanced healthcare infrastructure, high healthcare spending, and a large aging population with a growing prevalence of eye diseases. Additionally, significant investments in research, development, and the adoption of cutting-edge technologies drive market leadership in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

North America Ophthalmology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

North America Ophthalmology Market Leaders Operating in the Market Are:

• Alcon (Switzerland)
• Bausch + Lomb (Canada)
• Carl Zeiss Meditec( Germany)
• Hoya Corporation (Japan)
• Johnson & Johnson Services, Inc. (U.S.)
• Essilor International (France)
• Topcon Corporation(Japan)
• Glaukos Corporation (U.S.)
• Haag-Streit Group (Switzerland)
• Nidek Co., Ltd (U.S.)
• Staar Surgical (California)
• Ziemer Ophthalmic Systems Ag (Switzerland)
• Cooper Companies (U.S.)
• Lumenis Be Ltd. (Israel)
• Reichert Inc. (New York)
• Bayer Ag (Germany)
• Novartis Ag (Switzerland)
• Abbvie Inc. (U.S.)
• F. Hoffmann-La Roche Ltd.(Switzerland)
• Dompé (Italy)
• Santen Pharmaceutical Co.(Japan), Ltd

Latest Developments in North America Ophthalmology Market

• In October 2024, At the AAO 2024 meeting, Alcon showcased its innovations, including the Voyager DSLT for glaucoma treatment, UNIFEYE and UNIPEXY handheld gas delivery systems, and pivotal data for AR-15512, a dry eye treatment. These advancements aimed to improve outcomes and surgical efficiency
• In September 2024, EssilorLuxottica and Meta have extended their partnership, entering a long-term agreement to develop multi-generational smart eyewear products. Building on the success of Ray-Ban Meta glasses, the companies aim to shape the future of wearable technology together
• In OCTOBER 2024, Bausch + Lomb presented new scientific data and educational events at the 2024 AAO meeting in Chicago. Highlights included studies on the enVista Envy IOL, TENEO Excimer Laser, VYZULTA, and presentations on Blink Nutritears, MIEBO, and Xiidra
• In April 2024, AbbVie has completed its acquisition of Cerevel Therapeutics, enhancing its neuroscience portfolio. The acquisition includes Cerevel’s promising clinical-stage assets like Emraclidine for schizophrenia and Tavapadon for Parkinson's disease, strengthening AbbVie’s position in neurology and psychiatry
• In September, 2023, Novartis completed the divestment of its 'front of eye' ophthalmology assets to Bausch + Lomb for up to USD 2.5 billion, including USD 1.75 billion in upfront cash and potential milestone payments. The deal included Xiidra, SAF312, AcuStream, and OJL332. Novartis advanced its strategy to focus on prioritized therapeutic areas for future growth

SKU-69595